Búcsú a rosiglitazontól: Merre tovább?

Research output: Article

Abstract

The European Medicines Agency concluded that the marketing authorisation for all rosiglitazone-containing medicines (Avandia, Avandamet, Avaglim) should be suspended across the European Union. The National Health Insurance Fund Administration in Hungary in a circular letter called the attention of GP's to the necessity in getting the medical proposal (of an internist, endocrinologist or diabetologist) for substituting rosiglitazone to arrange a smooth modification of their treatment regimen. The review taking into account updated recommendations of the ADA-EASD and the Hungarian Diabetes Association summarises the potential drugs. The first line therapy of choice has to be starting with insulin. Pioglitazone might also be administered, with all known side effects of the glitazone family, e.g. congestive heart failure and bone fractures. Further alternatives are choosing the newer drugs of the incretin principle: the incretin mimetics (exenatid, liraglutid) and the incretin enhancers (sitagliptin, vildagliptin, saxagliptin). Beside their favourable profile of effect they do not have longterm follow up outcome studies and evidences for cardiovascular safety.

Original languageHungarian
Pages (from-to)805-811
Number of pages7
JournalLege Artis Medicinae
Volume20
Issue number12
Publication statusPublished - dec. 2010

Fingerprint

rosiglitazone
Incretins
pioglitazone
Thiazolidinediones
Hungary
Bone Fractures
National Health Programs
European Union
Marketing
Pharmaceutical Preparations
Heart Failure
Outcome Assessment (Health Care)
Insulin
Safety
Therapeutics

Keywords

  • Incretin enhancers
  • Incretin mimetics
  • Rosiglitazone

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Búcsú a rosiglitazontól : Merre tovább? / Tamás, G.; Kerényi, Z.

In: Lege Artis Medicinae, Vol. 20, No. 12, 12.2010, p. 805-811.

Research output: Article

@article{365ab2e64a8a46b3a8fbfe83933141cd,
title = "B{\'u}cs{\'u} a rosiglitazont{\'o}l: Merre tov{\'a}bb?",
abstract = "The European Medicines Agency concluded that the marketing authorisation for all rosiglitazone-containing medicines (Avandia, Avandamet, Avaglim) should be suspended across the European Union. The National Health Insurance Fund Administration in Hungary in a circular letter called the attention of GP's to the necessity in getting the medical proposal (of an internist, endocrinologist or diabetologist) for substituting rosiglitazone to arrange a smooth modification of their treatment regimen. The review taking into account updated recommendations of the ADA-EASD and the Hungarian Diabetes Association summarises the potential drugs. The first line therapy of choice has to be starting with insulin. Pioglitazone might also be administered, with all known side effects of the glitazone family, e.g. congestive heart failure and bone fractures. Further alternatives are choosing the newer drugs of the incretin principle: the incretin mimetics (exenatid, liraglutid) and the incretin enhancers (sitagliptin, vildagliptin, saxagliptin). Beside their favourable profile of effect they do not have longterm follow up outcome studies and evidences for cardiovascular safety.",
keywords = "Incretin enhancers, Incretin mimetics, Rosiglitazone",
author = "G. Tam{\'a}s and Z. Ker{\'e}nyi",
year = "2010",
month = "12",
language = "Hungarian",
volume = "20",
pages = "805--811",
journal = "Lege Artis Medicinae",
issn = "0866-4811",
publisher = "Literatura Medica Publishing House",
number = "12",

}

TY - JOUR

T1 - Búcsú a rosiglitazontól

T2 - Merre tovább?

AU - Tamás, G.

AU - Kerényi, Z.

PY - 2010/12

Y1 - 2010/12

N2 - The European Medicines Agency concluded that the marketing authorisation for all rosiglitazone-containing medicines (Avandia, Avandamet, Avaglim) should be suspended across the European Union. The National Health Insurance Fund Administration in Hungary in a circular letter called the attention of GP's to the necessity in getting the medical proposal (of an internist, endocrinologist or diabetologist) for substituting rosiglitazone to arrange a smooth modification of their treatment regimen. The review taking into account updated recommendations of the ADA-EASD and the Hungarian Diabetes Association summarises the potential drugs. The first line therapy of choice has to be starting with insulin. Pioglitazone might also be administered, with all known side effects of the glitazone family, e.g. congestive heart failure and bone fractures. Further alternatives are choosing the newer drugs of the incretin principle: the incretin mimetics (exenatid, liraglutid) and the incretin enhancers (sitagliptin, vildagliptin, saxagliptin). Beside their favourable profile of effect they do not have longterm follow up outcome studies and evidences for cardiovascular safety.

AB - The European Medicines Agency concluded that the marketing authorisation for all rosiglitazone-containing medicines (Avandia, Avandamet, Avaglim) should be suspended across the European Union. The National Health Insurance Fund Administration in Hungary in a circular letter called the attention of GP's to the necessity in getting the medical proposal (of an internist, endocrinologist or diabetologist) for substituting rosiglitazone to arrange a smooth modification of their treatment regimen. The review taking into account updated recommendations of the ADA-EASD and the Hungarian Diabetes Association summarises the potential drugs. The first line therapy of choice has to be starting with insulin. Pioglitazone might also be administered, with all known side effects of the glitazone family, e.g. congestive heart failure and bone fractures. Further alternatives are choosing the newer drugs of the incretin principle: the incretin mimetics (exenatid, liraglutid) and the incretin enhancers (sitagliptin, vildagliptin, saxagliptin). Beside their favourable profile of effect they do not have longterm follow up outcome studies and evidences for cardiovascular safety.

KW - Incretin enhancers

KW - Incretin mimetics

KW - Rosiglitazone

UR - http://www.scopus.com/inward/record.url?scp=78951486434&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78951486434&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:78951486434

VL - 20

SP - 805

EP - 811

JO - Lege Artis Medicinae

JF - Lege Artis Medicinae

SN - 0866-4811

IS - 12

ER -